To summarize, based on the genomic landscape under natural selection within lung cancer and CRC tumours, the clinical application of PLK1 inhibitors still needs to be approached with caution given potent tumour‐suppressor features of PLK1. This evidence concerns the gene PLK1 and neoplasm.